These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33907383)

  • 1. Temozolomide-Induced Changes in Gut Microbial Composition in a Mouse Model of Brain Glioma.
    Li XC; Wu BS; Jiang Y; Li J; Wang ZF; Ma C; Li YR; Yao J; Jin XQ; Li ZQ
    Drug Des Devel Ther; 2021; 15():1641-1652. PubMed ID: 33907383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut microbiota mediated the individualized efficacy of Temozolomide via immunomodulation in glioma.
    Hou X; Du H; Deng Y; Wang H; Liu J; Qiao J; Liu W; Shu X; Sun B; Liu Y
    J Transl Med; 2023 Mar; 21(1):198. PubMed ID: 36927689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glioma and temozolomide induced alterations in gut microbiome.
    Patrizz A; Dono A; Zorofchian S; Hines G; Takayasu T; Husein N; Otani Y; Arevalo O; Choi HA; Savarraj J; Tandon N; Ganesh BP; Kaur B; McCullough LD; Ballester LY; Esquenazi Y
    Sci Rep; 2020 Dec; 10(1):21002. PubMed ID: 33273497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Establishment of a mouse model bearing orthotopic temozolomide-resistant glioma].
    Shi L; Li H; Gu J; Song C; Li J; Chen L; Zhou Q; Qi S; Lu Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Jan; 41(1):69-74. PubMed ID: 33509755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma.
    Li PC; Chen SY; Xiangfei D; Mao C; Wu CH; Shih JC
    BMC Complement Med Ther; 2020 Aug; 20(1):252. PubMed ID: 32799864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomal circ-HIPK3 Facilitates Tumor Progression and Temozolomide Resistance by Regulating miR-421/
    Han C; Wang S; Wang H; Zhang J
    Cancer Biother Radiopharm; 2021 Sep; 36(7):537-548. PubMed ID: 32644821
    [No Abstract]   [Full Text] [Related]  

  • 7. Imaging temozolomide-induced changes in the myeloid glioma microenvironment.
    Foray C; Valtorta S; Barca C; Winkeler A; Roll W; Müther M; Wagner S; Gardner ML; Hermann S; Schäfers M; Grauer OM; Moresco RM; Zinnhardt B; Jacobs AH
    Theranostics; 2021; 11(5):2020-2033. PubMed ID: 33500706
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of Far-infrared Ray on Temozolomide-treated Glioma in Rats.
    Chen JC; Hwang JH
    In Vivo; 2019; 33(4):1203-1208. PubMed ID: 31280210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NCK1-AS1 Increases Drug Resistance of Glioma Cells to Temozolomide by Modulating miR-137/
    Chen M; Cheng Y; Yuan Z; Wang F; Yang L; Zhao H
    Cancer Biother Radiopharm; 2020 Mar; 35(2):101-108. PubMed ID: 31750728
    [No Abstract]   [Full Text] [Related]  

  • 10. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
    Towner RA; Ihnat M; Saunders D; Bastian A; Smith N; Pavana RK; Gangjee A
    BMC Cancer; 2015 Jul; 15():522. PubMed ID: 26177924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
    Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of circHIPK3 Facilitates Temozolomide Sensitivity in Glioma by Regulating Cellular Behaviors Through miR-524-5p/KIF2A-Mediated PI3K/AKT Pathway.
    Yin H; Cui X
    Cancer Biother Radiopharm; 2021 Sep; 36(7):556-567. PubMed ID: 32833501
    [No Abstract]   [Full Text] [Related]  

  • 13. β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species.
    Bi Y; Li H; Yi D; Bai Y; Zhong S; Liu Q; Chen Y; Zhao G
    Cancer Lett; 2018 Oct; 435():66-79. PubMed ID: 30081068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.
    Gong A; Ge N; Yao W; Lu L; Liang H
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):531-8. PubMed ID: 25047724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
    Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.
    Ohba S; Hirose Y; Kawase T; Sano H
    J Neurooncol; 2009 Dec; 95(3):307-316. PubMed ID: 19517066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effect of fibrin glue containing temozolomide against malignant glioma.
    Anai S; Hide T; Takezaki T; Kuroda J; Shinojima N; Makino K; Nakamura H; Yano S; Kuratsu J
    Cancer Sci; 2014 May; 105(5):583-91. PubMed ID: 24673719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circ_0005198 enhances temozolomide resistance of glioma cells through miR-198/TRIM14 axis.
    Deng Y; Zhu H; Xiao L; Liu C; Meng X
    Aging (Albany NY); 2020 Dec; 13(2):2198-2211. PubMed ID: 33316781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
    Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
    Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
    [No Abstract]   [Full Text] [Related]  

  • 20. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
    Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.